Identification and characterization of RET fusions in advanced colorectal cancer

Oncotarget

Volumn 6, Issue 30, 2015, Pages 28929-28937

  Le Rolle, Anne France ^a,b   Klempner, Samuel J ^a,b   Garrett, Christopher R ^c   Seery, Tara ^a,b   Sanford, Eric M ^d   Balasubramanian, Sohail ^d   Ross, Jeffrey S ^d,e   Stephens, Philip J ^d   Miller, Vincent A ^d   Ali, Siraj M ^d   Chiu, Vi K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d FOUNDATION MEDICINE   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Colorectal cancer; Comprehensive genomic profiling; RET fusion kinase; RET kinase inhibitor

Indexed keywords

B RAF KINASE; ERLOTINIB; HYBRID PROTEIN; K RAS PROTEIN; LENVATINIB; PROTEIN CCDC6; PROTEIN NCOA4; PROTEIN NRAS; PROTEIN PIK3CA; PROTEIN RET; PROTEIN TYROSINE KINASE; REGORAFENIB; UNCLASSIFIED DRUG; VANDETANIB; ANTINEOPLASTIC AGENT; CCDC6 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; NCOA4 PROTEIN, HUMAN; NUCLEAR RECEPTOR COACTIVATOR; PROTEIN KINASE INHIBITOR; RET PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CYTOTOXICITY; FEMALE; GENE EXPRESSION PROFILING; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN SYNTHESIS INHIBITION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE FUSION; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; PATHOLOGY; PHENOTYPE; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; DATABASES, GENETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; GENE FUSION; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NUCLEAR RECEPTOR COACTIVATORS; PHENOTYPE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; TIME FACTORS; TREATMENT OUTCOME;

EID: 84945152069     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4325     Document Type: Article

References (27)

1. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369:1023-1034.
2. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337.
3. Krause DS and Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005; 353:172-187.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, OhnoJones S and Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344:1031-1037.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139.
6. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014; 14:173-186.
7. Takahashi M, Ritz J and Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985; 42:581-588.
8. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18:382-384.
9. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H and Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18:378-381.
10. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G and Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994; 9:509-516.
11. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, Shen L, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012; 30:4352-4359.
12. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH and Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011; 129:245-255.
13. Matsubara D, Kanai Y, Ishikawa S, Ohara S, Yoshimoto T, Sakatani T, Oguni S, Tamura T, Kataoka H, Endo S, Murakami Y, Aburatani H, Fukayama M and Niki T. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol. 2012; 7:1872-1876.
14. Wells SA, Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ and Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012; 30:134-141.
15. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372:621-630.
16. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359:1757-1765.
17. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J and Modrusan Z. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and nonsmall cell lung cancers. Mol Cancer Res. 2009; 7:1466-1476.
18. Martin-Zanca D, Hughes SH and Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986; 319:743-748.
19. Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ and Varella-Garcia M. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res. 2014; 12:111-118.
20. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F, Huntley MA, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012; 488:660-664.
21. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, Boutin AT, et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011; 43:964-968.
22. Phay JE and Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010; 16:5936-5941.
23. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27:4247-4253.
24. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381:303-312.
25. Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013; 31:3639-3646.
26. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M and Rizvi N. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013; 3:630-635.
27. Gautschi O, Zander T, Keller FA, Strobel K, Hirschmann A, Aebi S and Diebold J. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol. 2013; 8:e43-44.